A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[125I]iodo-2′-deoxyuridine in glioblastoma cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 1, 2003, Pages 7-16

  Dupertuis, Y M ^a   Buchegger, F ^a   Pichard, Claude ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

5 125I Iodo 2 deoxyuridine; Cell proliferation; DNA incorporation; Glioblastoma; Nucleotides

Indexed keywords

DEOXYADENOSINE; DEOXYCYTIDINE; DEOXYGUANOSINE; DEOXYRIBONUCLEOSIDE; DEOXYURIDINE; DNA; IDOXURIDINE; IODINE 125;

ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0037223604     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803321269287     Document Type: Article

References (40)

1. Tsujinaka T, Kishibuchi M, Iijima S, Yano M, Monden M. Nucleotides and intestine. JPEN J Parenter Enteral Nutr, 23 (Suppl): S74 (1999).
2. Grimble GK, Westwood OM. Nucleotides as immunomodulators in clinical nutrition. Curr Opin Clin Nutr Metab Care, 4: 57-64. (2001).
3. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA, 286: 944-953 (2001).
4. Kulkarni AD, Rudolph FB, Van Buren CT. The role of dietary sources of nucleotides in immune function: a review. J Nutr, 124: 1442S-1446S (1994).
5. Matsumoto Y, Adjei AA, Yamauchi K, Kise M, Nakasone Y, Shinagawa Y, Yokoyama H, Yamamoto S. A mixture of nucleosides and nucleotides increases bone marrow cell and peripheral neutrophil number in mice infected with methicillin-resistant Staphylococcus aureus. J Nutr, 125: 817-822 (1995).
6. Nunez MC, Ayudarte MV, Morales D, Suarez MD, Gil A. Effect of dietary nucleotides on intestinal repair in rats with experimental chronic diarrhea. JPEN J Parenter Enterai Nutr, 14: 598-604 (1990).
7. Bueno J, Torres M, Almendros A, Carmona R, Nunez MC, Rios A, Gil A. Effect of dietary nucleotides on small intestinal repair after diarrhoea. Histological and ultrastructural changes. Gut, 35: 926-933 (1994).
8. Sanderson IR, He Y. Nucleotide uptake and metabolism by intestinal epithelial cells. J Nutr, 124 (Suppl): 131S-137S (1994).
9. Iwasa Y, Iwasa M, Ohmori Y, Fukutomi T, Ogoshi S. The effect of the administration of nucleosides and nucleotides for parenteral use. Nutrition, 16: 598-602 (2000).
10. Walsh MJ, Sanchez-Pozo A, Leleiko NS. A regulatory element is characterized by purine-mediated and cell-type-specific gene transcription. Mol Cell Biol, 10: 4356-4364 (1990).
11. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res, 43: 3466-3492 (1983).
12. He Y, Chu SH, Walker WA. Nucleotide supplements alter proliferation and differentiation of cultured human (Caco-2) and rat (IEC-6) intestinal epithelial cells. J Nutr, 123: 1017-1027 (1993).
13. 125I]iodo-2′-deoxyuridine. Radiat Res, 118: 532-544 (1989).
14. 125I after incorporation into the DNA of the mouse. Nature, 206: 949-950 (1965).
15. Neshasteh-Riz A, Angerson WJ, Reeves JR, Smith G, Rampling R, Mairs RJ. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer, 75: 493-499 (1997).
16. O'Donoghue JA. Strategies for selective targeting of Auger electron emitters to tumor cells. J Nucl Med, 37 (Suppl): 3S-6S (1996).
17. Klecker RWJ, Jenkins JF, Kinsella TJ, Fine RL, Strong JM, Collins JM. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clin Pharmacol Ther, 38: 45-51 (1985).
18. 125I-iododeoxyuridine in 2 human glioblastoma cell lines. Nucl Med Commun, 21: 947-953 (2000).
19. Dupertuis YM, Vazquez M, Mach JP, De Tribolet N, Pichard C, Slosman DO, Buchegger F. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Research, 61: 7971-7977 (2001).
20. 125I]iododeoxyuridine in human xenografted glioblastomas. Eur J Nucl Med, 29: 499-505 (2002).
21. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Su Huang H-J, Friedmann T, de Tribolet N, Cavenee WK. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res, 54: 649-652 (1994).
22. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res, 58: 1793-1797 (1998).
23. 131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire. Br J Cancer, 77: 385-390 (1998).
24. Mairs RJ, Wideman CL, Angerson WJ, Whateley TL, Reza MS, Reeves JR, Robertson LM, Neshasteh-Riz A, Rampling R, Owens J, Allan D, Graham DI. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. Br J Cancer, 81: 74-80 (2000).
25. 3H-labeled 5-iodo-2′-deoxyuridine. Cancer Res, 29: 1717-1720 (1969).
26. 131iododeoxyuridine into the DNA of tumour-bearing rats after partial synchronization as a tool in scintigraphic tumour localization. Nucl Med (Stuttg), 12: 309-319 (1974).
27. 125I-iododeoxyuridine as protype for radionuclide therapy with Auger emitters. Nature, 265: 620-621 (1977).
28. Robins AB, Taylor DM. Iodine-123-iododeoxyuridine: a potential indicator of tumour response to treatment. Int J Nucl Med Biol, 8: 53-63 (1981).
29. 125IUDR labelling efficiency and cytotoxicity for murine tumours in vivo and in vitro. Eur J Nucl Med, 7: 108-114 (1982).
30. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys, 21: 1541-1551 (1991).
31. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res, 59: 615-621 (1999).
32. 124I]iodo-deoxyuridine. Cancer Res, 60: 624-635 (2000).
33. 125I]iodo-2-deoxyuridine. Acta Oncol, 39: 731-737 (2000).
34. 123I]iodo-2′-deoxyuridine in a patient with a brain tumor. J Nucl Med, 37 (Suppl): 19S-22S (1996).
35. 125I]iodo-2′-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med, 39: 1148-1154 (1998).
36. Kim JH, Kim SH, Eidinoff L. Cell viability and nucleic acid metabolism after exposure of HeLa cells to excess thymidine and deoxyadenosine. Biochem pharmacol, 14: 1821-1829 (1965).
37. Grimble GK, Malik SB, Boza JJ. Methods for measuring tissue RNA turnover. Curr Opin Clin Nutr Metab Care, 3: 399-408 (2000).
38. Carver JD. Dietary nucleotides: effects on the immune and gastrointestinal systems. Acta Paediatr, 88 (Suppl): 83-88 (1999).
39. Savaiano DA, Ho CY, Chu V, Clifford AJ. Metabolism of orally and intravenously administered purines in rats. J Nutr, 110: 1793-1804 (1980).
40. Liu MP, Beigelman L, Levy E, Handschumacher RE, Pizzorno G. Discrete roles of hepatocytes and nonparenchymal cells in uridine catabolism as a component of its homeostasis. Am J Physiol, 274: G1018-G1023 (1998).